Compare OXBR & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXBR | HKPD |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Cayman Islands | Hong Kong |
| Employees | 4 | 27 |
| Industry | Property-Casualty Insurers | Other Pharmaceuticals |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0M | 6.9M |
| IPO Year | N/A | N/A |
| Metric | OXBR | HKPD |
|---|---|---|
| Price | $0.99 | $0.53 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | 23.0K | ★ 90.4K |
| Earning Date | 05-11-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $80.09 | N/A |
| Revenue Next Year | $85.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.66 | $0.37 |
| 52 Week High | $2.85 | $2.58 |
| Indicator | OXBR | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 57.16 | 37.04 |
| Support Level | $0.99 | $0.45 |
| Resistance Level | $1.05 | $0.71 |
| Average True Range (ATR) | 0.07 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 90.00 | 29.67 |
Oxbridge Re Holdings Ltd is a specialty property and casualty reinsurer that provides reinsurance solutions through its subsidiary. The company focuses on underwriting fully collateralized reinsurance contracts for property and casualty insurance companies in the Gulf Coast region of the United States, with an emphasis on Florida. It specializes in underwriting medium-frequency, high-severity risks where insufficient data exists to effectively analyze the risk/return profile of reinsurance contracts. The company generates revenue from three principal sources: premiums assumed from reinsurance on property and casualty business; income from investments, including unrealized gains or losses on other investments; and income from SurancePlus management fees.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.